Targeting leukemia cells
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jul 3, 2003
app pub date -
Dec 6, 2002
filing date -
Dec 6, 2001
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
A molecule is targeted to a leukemia cell by first contacting the cell with a retinoid in an amount effective to increase the expression of a marker in the cell, and the contacting the cell with an agent that specifically binds the marker. For directing a molecule to an acute promyelocytic leukemia cell, the cell is contacted with all-trans retinoic acid to induce or increase expression of CD52 on the cell. The cell is then contacted with a molecule, such as an anti-CD52 antibody, that specifically binds the CD52 expressed on the cell.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully